Soheil Meshinchi, MD, PhD, is attending physician at Seattle Childrens Hospital, associate professor at the University of Washington School of Medicine and associate member of Fred Hutchinson Cancer Research Center (FHCRC). He attends on the Hematopoietic Stem Cell Transplant Service. He is co-director of the COG Myeloid Resource Laboratory, chairman of the COG Myeloid Disease Biology Committee, Vice chair of the COG Myeloid Disease committee and the Biology chair and vice chair of the COG acute myeloid leukemia (AML) phase III trial.
, he serves on several COG committees, including the committee for development of new APL therapy, phase III AML committee, phase II trial of STI571 for Philadelphia chromosome leukemias and the infant leukemia steering committee. Dr. Meshinchis clinical and research interests center around the treatment of pediatric myeloid leukemia. He is principal investigator on ten research projects at FHCRC and Seattle Childrens, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification. He supervises the treatment and management of all patients with myeloid diseases (AML, MDS, etc.) in the Seattle Cancer Care Alliance, and he is working to identify novel therapies in AML.
View More
Education Background
RESIDENCY
University Of Washington School Of Medicine
MEDICAL SCHOOL
Wayne State University School Of Medicine - 1994
Languages Spoken
English
Location & Hours
Fred Hutchinson Cancer Center
1959 Ne Pacific St, Seattle, WA 98195
Specialties Treated
Pediatric Hematology-Oncology
Conditions Addressed
Leukemia
Non-Hodgkin's Lymphoma
Anemia
Procedures Performed
Chemotherapy
Insurance Accepted
* Insurance information may change frequently. Please verify directly with the provider (doctor/clinic).